Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197897 · ClinicalTrials.gov registry record · Phase 2
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
A Phase 2 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02197897: Completed Phase 2 study, sponsored by Baylor College of Medicine.
NCT02197897 is a Phase 2 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02197897, a Phase 2 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors
Primary Outcome
Evaluate the efficacy of tamoxifen for treatment of low/intermediate-risk bladder tumors, utilizing the RECIST criteria combined with the final biopsy of the marker lesion or the bed of the lesion in case of a complete response
Interventions
- DRUG Tamoxifen Citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 2 |
What the finished NCT02197897 record still lists
NCT02197897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Tamoxifen Citrate is the first listed.
NCT02197897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02197897 about?
NCT02197897 is a clinical study titled "Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors". Evaluate the treatment of tamoxifen of low/intermediate-risk bladder tumors
What is the current status of trial NCT02197897?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2015-04-01. Estimated completion is 2019-06-28.
What interventions are being tested in trial NCT02197897?
The interventions under investigation include: Tamoxifen Citrate (DRUG).
Who is sponsoring clinical trial NCT02197897?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02197897's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI